John P.Daly Jr. (@JohnPDalyJr) header
John P.Daly Jr. (@JohnPDalyJr) profile picture

The Gentleman from Indiana. BA, MPA, JD. Noblesse oblige.

Indiana, USA
Joined January 2018
Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)Photo by John P.Daly Jr. (@JohnPDalyJr)
John P.Daly Jr. retweeted
We are honored to join this journey. New approaches are needed in the “hunt” for an effective therapy. $LCTX. innovation.uci.edu/news/neur…
1
2
3
159
John P.Daly Jr. retweeted
Replying to @annmarie
The market needs to appreciate how protected the president has been by Republican majorities in the House and Senate. That is over in a few weeks. The Great Unraveling will begin thereafter. @agf @VedaPartners1
3
2
15
1,423
John P.Daly Jr. retweeted
Before you laugh at kids for believing in Santa Claus and the Easter Bunny, remember that there are adults who believe in Donald Trump.
19
373
11
3,609
31,284
John P.Daly Jr. retweeted
Social Security tax stops at roughly $170,000 of income. Someone earning $20 million pays the same as someone earning $170,000. Raising that cap is the fix almost nobody wants to debate.
700
412
54
3,555
278,831
John P.Daly Jr. retweeted
1/🚨WOW! Intellia Theraputics has just presented clinical data with a follow-up of up to 48 months (!) from its ongoing Phase 1 study of Nex-z / $NTLA - 2001 - Intellia’s CRISPR Cas-9 Gene Editing candidate for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Today’s data demonstrates that a one-time administration of Nex-z led to a deep, consistent and durable reductions of serum TTR in ATTRv-PN patients with mean reductions of 93% from baseline which was sustained through four years of follow-up!
8
18
1
69
7,135
Replying to @CEO_Culley
@CEO_Culley, CEO of $LCTX, is looking forward to joining fellow industry leaders at @FierceBiotech’s virtual event, "Cell and Gene Therapy at a Crossroads: Scaling Innovation, Expanding Access" on November 18. Brian will participate in the panel “The Cost Curve Problem: Can Cell and Gene Therapy Become Economically Viable?” alongside Joakim Vinberg, Head of U.S. Trade, Pricing and Contracting at @KitePharma, and William Ho CEO and Co-Founder @IN8bio, for a discussion moderated by @Fraiser_K on the challenges of making cell and gene therapies more economically viable and what it will take to expand patient access. Register now: bit.ly/48IF3Tf #celltherapy #genetherapy #RegenerativeMedicine #virtualevent
1
4
8
451
John P.Daly Jr. retweeted
Japan granted full approval to STEMIRAC, Nipro's therapy made from a patient's own bone marrow stem cells (MSCs) for spinal cord injury. It is Japan's first regenerative product to go from conditional to full approval, after 7 years of comparison data. nipro.com/news-and-events/ne…
6
13
589
“Finish every day and be done with it. For manners and for wise living it is a vice to remember. You have done what you could; some blunders and absurdities no doubt crept in; forget them as soon as you can. To-morrow is a new day; you shall begin it well and serenely, and with too high a spirit to be cumbered with your old nonsense. This day for all that is good and fair. It is too dear, with its hopes and invitations, to waste a moment on the rotten yesterdays.”-Emerson
54
Biotech stocks trading today like all its CEOs are having extramarital sex with Jensen Huang.
39
20
11
544
38,897
John P.Daly Jr. retweeted
Rich in Indiana.
57
79
19
2,363
990,478
John P.Daly Jr. retweeted
Allarta won a Breakthrough T1D award to finish lab work on LifeSpheres, a gel coating that shields insulin cells from the immune system. In diabetic mice and rats, coated islets controlled blood sugar for weeks without rejection drugs. stemcelltracker.com/news/typ…
1
1
7
659
John P.Daly Jr. retweeted
Stanley Druckenmiller on his $1 billion profit trade on the British pound: “I didn’t know whether the pound was going to devalue. What I did know was, if they didn’t devalue in the next 6 months, my fund was going to lose 50 basis points. If they did devalue, I was going to make 2000 basis points. So it was a 40 to 1, one-way risk to reward bet.”
3
32
2
239
16,256
Imagine how much time and care went into creating these ceilings. Hundreds of years later, we're still looking up in awe. I wish we built more things like this today.
We used to look up ✨️
5
5
76
11,135
$BTC.X Relax. This is a bet on governments continuing to overspend their income. Historically an excellent wager.
47
John P.Daly Jr. retweeted
The same people who think Democrats are Socialists think Donald Trump is a Christian.
110
927
33
5,896
56,294
John P.Daly Jr. retweeted
reversing this concentration is one of the great opportunities for our species in the coming years
77% of clinical-stage drugs go after the most popular 20% of targets, and 31% after the top 2%
7
12
1
137
6,635
“Call your mother. Write a thank-you note by hand. Put on a jacket tonight, even if no one else does. Hold the door for the person behind you. Learn your waiter's name, and use it. Stand when a lady comes to the table. Finish the conversation before you finish the wine. Listen to the man you disagree with, and shake his hand anyway. Put the phone face down. Better yet, put it away. Tip generously. Keep your word, even if it costs you. Check on your friends and family. Leave every room a little better than you found it. The days may seem long, but the years go fast. We get one life, so live it well.” - J.B. Lloyd
73
921
73
5,982
211,594
John P.Daly Jr. retweeted
1/🚨WOW! @LineageCell has just announced that the it is expanding its pipeline via the acquisition of NeuroAirmid Therapeutics for $4.7M - half in cash and half in equity via $LCTX shares. The acquisition includes worldwide rights for hNSC-01 - which Lineage renamed HUNT1 - NeuroAirmid’s clinical-stage neural Cell Therapy program for the treatment of Huntington’s Disease (HD), and all of the data from the ongoing REGEN4HD clinical trial. It’s great to see Lineage entering the neural Cell Therapy field and strengthening its clinical pipeline. Kudos to @CEO_Culley for making this deal! $XBI
2
5
1
18
2,365
$LCTX announces the acquisition of NeuroAirmid Therapeutics, Inc. along with certain worldwide rights to HUNT1 (hNSC01), a pluripotent stem cell derived clinical-stage neural cell therapy program for the treatment of Huntington's Disease. This acquisition adds a third clinical stage asset to Lineage's development pipeline, and aligns with the company's capabilities in cell manufacturing, process development, and scale-up. The HUNT1 program represents the culmination of decades of research led by Leslie Thompson, Ph.D., and is currently being evaluated in the #REGEN4HD clinical study at @UCIrvineHealth. For more details, see here: investor.lineagecell.com/new… #CellTherapy #HuntingtonDisease #RegenerativeMedicine #UniversityofCaliforniaIrvine @CEO_Culley @CIRMNews @HDSA @HuntingtonSG @hdfcures
3
3
2
20
1,270